Phase 1 N=58 A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants
Healthy
Primary: Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Insulin Glargine and Lantus — 124; 129 picomole per liter (pmol/L)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=47 Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection
HIV Infections
Primary: Percentage of Participants Failing to Meet Safety Endpoint Related to Maraviroc for Dose-Finding — 0; 0; 0; 0 percentage of participants
Phase 1 N=105 Duration of Effect of Acidform Gel on Vaginal pH
Healthy
Primary: Change in Vaginal pH Following a Single Dose of Acidform (3, 4, and 5 g), HEC Placebo (4 g), or no Intervention. — 4.85; 4.81; 4.91; 5.00 pH
Phase 1 N=24 Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039)
Obstructive Sleep Apnea (OSA)
Primary: Apnea-Hypopnea Index (AHI) Change From Baseline as Calculated From Polysonagraphy (PSG) — 0.86; 0.97 ratio
Phase 1 N=15 Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma
Advanced Solid Neoplasm · Aggressive Non-Hodgkin Lymphoma · Recurrent Solid Neoplasm
Primary: Maximum Tolerated Dose (MTD) — 400 mg
Phase 1 N=15 A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease
Alzheimer's Disease
Primary: Number of Participants With Vital Signs Abnormalities of Potential Clinical Concern — 0; 0; 0; 0 participants
Phase 1 N=16 Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2831781 After an Intravenous (IV) Dose in Healthy Japanese and Caucasian Subjects, and a Subcutaneous (SC) Dose in Healthy Caucasian Subjects
Healthy Volunteers
Primary: Part A: Number of Participants With Serious Adverse Events (SAEs) and Non-serious Adverse Events (Non-SAEs) — 2; 5; 0; 4 Participants
Phase 1 N=58 Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Participants With Narcolepsy
Healthy Participants and Patients With Narcolepsy
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) — 1; 1; 1; 1 Participants
Phase 1 N=31 Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)
Relapsed or Refractory Multiple Myeloma
Primary: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Phase 1 N=19 Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Normal Renal Function and Severe Renal Impairment
Hepatitis C Virus
Primary: Pharmacokinetic (PK) Parameter of Velpatasvir: AUClast — 5597.8; 7971.7 h*ng/mL
Phase 1 N=17 Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients
Ovarian Neoplasms · Neoplasms · Solid Tumor
Primary: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Niraparib and Its Major Metabolite (M1) During…
Phase 1 N=3 Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
Ovarian Cancer
Primary: Part A: Number of Participants With Dose Limiting Toxicities (DLTs) — 0 Participants
Phase 1 N=27 Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder
Opioid Abuse · Opioid Dependence · Opioid-Related Disorders
Primary: Change in Subjective Response to Oxycodone Measured With 100 Millimeter Visual Analog Scale — -13.81; -9.67 units on a scale
Phase 1 N=32 A Dose-escalating Clinical Trial With KH176
MELAS · LHON · Leigh Syndrome
Primary: SAD: Change From Baseline in ECG Results by Timepoint: Corrected QT Interval According to Fridericia's Formula (QTcF) — 386.2; 395.0; 385.8; 399.3 msec
Phase 1 N=9 Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients
Hemophilia B
Primary: Number of Adverse Events (AEs) After the Administration of Investigational Products (IP) — 0; 10; 10; 69 adverse events